Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Posting of Shareholder Circular

14th Apr 2015 15:59

RNS Number : 2044K
Sphere Medical Holding plc
14 April 2015
 

14 April 2015

 

Sphere Medical Holding plc

Posting of Shareholder Circular

 

Cambridge, UK, 14 April 2015: Sphere Medical Holding plc (AIM: SPHR.L), ("Sphere" or "Sphere Medical" or the "Company") a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announces that, further to the announcement on 13 April 2015, which gave details of the Company's proposed fundraising through a Placing and Open Offer, it has posted the circular and application form in connection with the open offer to shareholders on 13 April 2015. The circular contains the notice convening the General Meeting to be held at the offices of Taylor Wessing LLP, 5 New Street Square, London EC4A 3TW on 30 April 2015 at 10.00 a.m.

 

A copy of the circular is available on the Company's website: www.spheremedical.com.

 

For further information, please contact:

 

Sphere Medical Holding plc

Tel: +44 (0)1223 875 222

Dr Wolfgang Rencken, Chief Executive Officer

Matthew Hall, Chief Financial Officer

Peel Hunt LLP

Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

Jock Maxwell Macdonald

finnCap

Tel: +44 (0) 20 7220 0500

Geoff Nash / Simon Hicks

Stephen Norcross

Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott

[email protected]

Amber Bielecka

Matthew Neal

Ivar Milligan

 

Notes for Editors

About Sphere Medical (AIM: SPHR.L)

 

Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

 

Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.

 

The Company's strategy is focused on developing the Proxima (CE marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already marketing its Proxima product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK. Sphere has plans to follow in Germany and Benelux via a direct sales force in Europe and proposes to work with partners for worldwide distribution.

 

Proxima delivers near real time analysis of blood gases and electrolytes metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.

 

Sphere Medical entered into a collaboration agreement with Ortho-Clinical Diagnostics, Inc. in 2013 for the development of Proxima and enhancement of Sphere's operational and production capabilities.

 

Sphere Medical has a number of partnerships with industry leading medical device companies and has received a strategic investment from Ortho-Clinical Diagnostics (now part of Carlyle Group).

 

For further information, please visit www.spheremedical.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIIMITMBABBPA

Related Shares:

Sphere Medical Holding
FTSE 100 Latest
Value8,809.74
Change53.53